Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
The YouTube video is real according to an  October 12, 2012 news article by ABC News Nightline. The article said, “Amanda Todd, 15, posted the video called ‘My story: Struggling, bullying, suicide, self harm’ on Sept. 7 and was found dead in her home town of Port Coquitlam, British Columbia, just over a month later.”    The article also said that Todd had been coaxed by a stranger on the internet to flash her chest via webcam. After about a year of prompting by the stranger she eventually gave in and the events that followed escalated into a teen’s nightmare. A photo of the session was posted on the Internet and someone contact her though Facebook threatening her that if she did not “put on a show” that the photo would be released. The article went on to say, “Over Christmas break, Todd said police came to her house at 4 a.m. to tell her that the photo had been sent to everyone. ‘I then got really sick and got anxiety, major depression and panic disorders,’ she wrote. ‘I then moved and got into drugs and alcohol. '” The cyber-bullies followed her move to a new school in another city and eventually the attacks not only came from the Internet but also from her new classmates who prompted her to find another school. The article said that in the early evening of October 10th law enforcement were called to a home in Port Coquitlam, British Columbia, “to investigate the sudden death of the tormented teenager.”  Investigators found no evidence of foul play but the Royal Canadian Mounted Police have yet to rule her death a suicide. updated 10/15/12 Comments

Ex Output:
 This is a YouTube video that is circulating the Internet allegedly by a 15 year old girl called Amanda Todd.   She tells how someone on the Internet coaxed her into flashing her chest in a webcam session and how the events that followed led to depression, addiction and her suicide. 


Ex Input:
The FDA said it received 85 reports from patients who switched from Wellbutrin XL to Teva Pharmaceutical Industries Ltd and Impax Laboratories Inc’s cheaper generic, including 78 who said they slipped back into depression. Other patients reported new or worsening side effects, including headaches, fatigue, anxiety and digestion issues. “The question is whether the reported lack of efficacy and/or new onset side effects in these patients who switched suggest a problem with the generic product ... or have some other explanation,” the FDA said in a statement on its website. Agency scientists reviewed 300-milligram versions of the two drugs, which both use once-a-day formulations of the chemical bupropion, and found the data did not show that the problems stemmed from any differences between the two drugs. One factor that could account for the reported problems is the natural recurrence of depression, which can happen despite treatment, the FDA said. Half of the patients who went back on the name-brand drug said they improved, the agency said, adding that it would continue to monitor the issue. FDA officials received the reports during the first half of 2007. Teva and Impax’s version of Wellbutrin was approved in 2006. Watson Pharmaceuticals Inc also makes a 300-mg XL version of bupropion, though it was not part of the FDA’s review. GlaxoSmithKline makes other versions of Wellbutrin that face generic competition. Total sales of Wellbutrin slipped 37 percent last year in the face of generic competition, the company has reported. The drugmaker could not comment on the FDA’s conclusion because it did not have access to the data used but is pleased the agency would continue its monitoring, GlaxoSmithKline spokeswoman Mary Anne Rhyne said. Teva spokeswoman Denise Bradley said the company would issue a statement later. Shares of GlaxoSmithKline rose 39 cents to $42.47 on the New York Stock Exchange. Teva rose 65 cents, or 1.4 percent, to $46.67 on Nasdaq.

Ex Output:
FDA says generic Wellbutrin OK despite reports.


Ex Input:
The analysis suggests the potentially harmful effect of Celebrex dosage is most pronounced in higher-risk patients, researchers said at the American College of Cardiology scientific meeting. “Patients at low cardiovascular risk should take some level of comfort,” said Dr. Scott Solomon, lead researcher of the National Cancer Institute-sponsored analysis. “That wasn’t so clear previously.”   Doctors should exercise caution in prescribing the drug, generally known as celecoxib, in high-risk patients, said Solomon, whose analysis was also published online in the journal Circulation. Celebrex belongs to a class of pain drugs known as cox-2 inhibitors and is the only such drug still on the market in the United States. Merck and Co Inc withdrew its widely used cox-2 drug, Vioxx, from the market in 2004 after a study showed it doubled the risk of heart attack and stroke in long- term users. Another cox-2 inhibitor from Pfizer called Bextra was also pulled from the U.S. market due to safety concerns. While the analysis sheds light on how the drug should be used, Solomon said he could not judge whether the data lift the cloud over this class of drugs. The six trials involving a total of 7,950 patients all studied Celebrex against a placebo for uses other than arthritis. Patients received either 400 milligrams once a day, 200 mg twice a day, or 400 mg twice a day. The primary goal of the pooled analysis was an assessment of the combined risk of cardiovascular death, heart attack, stroke, heart failure or events involving blood clots. Researchers found the heart risk was lowest at the 400 mg daily dose. They found nearly a two-fold risk of adverse heart events with the 200 mg twice daily dose and that jumped to about a three-fold risk at the 400 mg twice daily dose. “Even 400 mg once a day showed elevated risk” in the high-risk population, Solomon said, adding he could not extrapolate whether doses lower than 400 mg cut risk further. The increased risk was not affected by aspirin use, researchers said. “Most of the data used in this pooled analysis have previously been published and are consistent with what we already know about the cardiovascular risks of Celebrex and other prescription arthritis pain relievers,” said Gail Cawkwell, Pfizer’s executive medical director. “The analysis doesn’t provide any new conclusions on the FDA-approved doses of Celebrex, including the most commonly prescribed dose of 200 mg daily,” she said. Dr. Steven Nissen of the Cleveland Clinic, who has a study on lower doses underway, added: “There aren’t long-term randomized placebo-controlled trials for that dose, The only way we’re ever going to answer these questions is with good randomized prospective data,” he said. “We’ll tell it like it is when the data is in.”

Ex Output:

Celebrex risky in high-risk patients, study finds.